OCUL
Ocular Therapeutix, Inc. · Healthcare
Insiders bought $461K of Ocular Therapeutix, Inc. in the last 12 months
1 insider bought on 1 day.
OCUL over the last year
Largest buyers, last 12 months
OCUL after insider buys
3 months after each buy, from the first price a copier could get.
8 buys since 2016 with 3 months of prices.
Every filing
69 insider filings since 2016, newest first
Todd Anderman · Chief Legal Officer
Peter Kaiser · Chief Development Officer
Jeffrey S. Heier · Chief Scientific Officer
Peter Kaiser · Chief Development Officer
Jeffrey S. Heier · Chief Scientific Officer
Pravin Dugel · Insider
Nadia Waheed · Chief Medical Officer
Pravin Dugel · Insider
Pravin Dugel · Insider
Jeffrey S. Heier · Chief Scientific Officer
Richard L Md Lindstrom · Director
Nadia Waheed · Chief Medical Officer
Pravin Dugel · Insider
Donald Notman · COO
Nadia Waheed · Chief Medical Officer
Pravin Dugel · Insider
Peter Kaiser · Chief Development Officer
Jeffrey S. Heier · Chief Scientific Officer
Richard L Md Lindstrom · Director
Pravin Dugel · Insider
Jeffrey S. Heier · Chief Scientific Officer
Peter Kaiser · Chief Development Officer
Pravin Dugel · Insider
Pravin Dugel · Insider
Summer Road LLC · 10% owner
Christopher G White · Chief Business Officer
Philip C. Strassburger · General Counsel
Rabia Gurses Ozden · Chief Medical Officer
Donald Notman · CFO
Antony C. Mattessich · President and CEO
Donald Notman · CFO
Rabia Gurses Ozden · Chief Medical Officer
Philip C. Strassburger · General Counsel
Christopher G White · Chief Business Officer
Antony C. Mattessich · President and CEO
Summer Road LLC · 10% owner
Rabia Gurses Ozden · Chief Medical Officer
Donald Notman · CFO
Philip C. Strassburger · General Counsel
Antony C. Mattessich · President and CEO
Summer Road LLC · 10% owner
Summer Road LLC · 10% owner
Summer Road LLC · 10% owner
Summer Road LLC · 10% owner
Antony C. Mattessich · President and CEO
Richard L Md Lindstrom · Director
Summer Road LLC · 10% owner
Summer Road LLC · 10% owner
Summer Road LLC · 10% owner
Summer Road LLC · 10% owner
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.